|
AM |
Keynote Address |
| Session 1:
Acknowledging the trends and challenges of
the growing IVD Market in India |
| Session 2:
Transitioning from clinical discovery towards
commercialization in global IVD market |
Morning Interaction  |
| Molecular Diagnostics |
| Session 3:
The impact of genetic & epigenetic evaluation of Human Disease: What do you need to know! |
| Session 4:
Emerging practices in Molecular Diagnostics
for Cancer |
| |
Special Discussions |
| |
Session 5:
The Arena of Novel Diagnostics System: A thorough navigation tracking the development and challenges of diagnostics performance in complicated human genomes |
|
Luncheon |
PM |
Point-Of-Care (POC) |
| Session 6:
Development of a translational Point-Of-Care
(POC) Platform: Restraints and advancement
of POC in Immunoassays |
| Session 7:
Disposable Chip Technology: Exploring the
efficacy of new chip technology in Point-Of-
Care Testing |
| Afternoon Interaction |
| Panel Discussion |
| Session 8:
The Menace of Emerging Infections: The race of IVD in prompt diagnosis towards curbing and curing epidemics. |
| Closing Remarks from Chairman and End of Day One |
|
AM |
Pharmacogenomics & Theranostics |
| Session 1:
Genetic Basis of Human Drug Response: A Path
towards Personalized Medicine |
| Session 2:
The integrated role, advantages and
challenges of Theranostics in shaping a result
driven clinical research |
| Morning Interaction |
| Emerging Technologies |
| Session 3:
Prospect of Biochips and Nanotechnology to
improve Molecular Diagnostics |
| Session 4:
Application of Nanomaterials for Cancer
Treatment & the targeted drug Diagnostics |
| |
Biomarkers (KEY) |
| |
Session 5:
Identify the importance of pre-analytical variants in biomarker discovery using proteomics approach |
|
Luncheon |
PM |
Regulatory |
| Session 6:
Complexities in biomarker development for theranostic application in Scizophrenia |
|
| Session 7:
Evaluating and determining the measures for safety and quality of IVD products during clinical practice |
| Afternoon Interaction |
| Panel Discussion |
| Session 8:
Delving into Evolutions of Clinical Trials: Navigating the current and emerging approach of IVD testing to alleviate and minimize the hurdles in future clinical testing |
| Closing Remarks from Chairman and End of Day Two |
